Alexa

Amgen 3Q profit jumps 24 pct. on stronger sales

Biotech drugmaker Amgen's 3Q profit jumps 24 percent on stronger sales of most of its drugs

Amgen 3Q profit  jumps 24 pct. on stronger sales

TRENTON, New Jersey (AP) -- Biotech drugmaker Amgen Inc. says its third-quarter profit jumped 24 percent and beat analysts' expectations as sales of more than a half-dozen of its drugs increased by double digits.

Amgen, which sells arthritis treatment Enbrel and Prolia for osteoporosis, says net income was $1.37 billion, or $1.79 per share, up from $1.11 billion, or $1.41 per share, a year earlier.

The Thousand Oaks, California-based company says earnings were $1.94 per share excluding one-time items. Analysts were expecting $1.76 per share.

Revenue was up 10 percent at $4.75 billion. Analysts expected $4.6 billion.

The company also raised the lower end of its 2013 profit forecast by a nickel and now expects $7.35 to $7.45 per share.